

Nifty Futures	Level 1	Level 2	Level 3
Resistance	12360	12420	12500
Support	12280	12230	12180

Indices (NSE)	Close	Pts. Chg	% Chg
Nifty	12329.6	72.8	0.6
Nifty Future (Jan)	12636.9	73.9	0.6
Nifty Future (Feb)	12402.6	71.9	0.5
Bank Nifty	32177.7	80.3	0.3
Nifty 100	12436.5	76.8	0.6
Nifty 500	10042.5	64.5	0.6
Nifty Midcap	17527.5	141.2	0.8

Indices (BSE)	Close	Pts. Chg	% Chg
Sensex	41859.7	260.0	0.6
BSE-100	12412.2	76.8	0.6
BSE-200	5155.1	32.8	0.6
BSE-500	4528.2	31.1	0.7
Mid Cap	15290.1	131.2	0.9
Small Cap	14282.1	134.5	1.0

Sectoral Indices	Close	Pts. Chg	% Chg
BANKEX	36680.9	82.5	0.2
CAPITAL GOODS	17366.5	112.5	0.7
REALTY	2424.1	50.3	2.1
POWER	1972.9	20.3	1.0
OIL & GAS	14719.5	98.7	0.7
METAL	10669.1	119.0	1.1
CD	25081.5	222.4	0.9
AUTO	18460.6	18.8	0.1
TECK	7956.9	141.2	1.8
IT	16052.1	291.7	1.9
FMCG	11652.6	138.9	1.2
HEALTHCARE	13635.5	56.4	0.4
VIX	14.3	0.2	1.4

Exchange	Advance	Decline	Unchg
BSE	1553	974	184
NSE	1202	661	119

Volume	Rs (in cr)	% Chg
NSE Cash	32247	-9.8
BSE Cash	3100	0.4
NSE F&O	874840	-16.1

Net Inflows/ Outflows (Rs in cr)	Buy	Sell	Net
FII	4883.9	4815.6	68.2
DII	4593.4	4546.2	47.2

Intraday Nifty Outlook

Nifty spot closed 0.59% higher at 12330. Index opened gap up and remained strong throughout the day closing the day at all time highs. Going ahead index to continue its upmove will have surpass and sustain above 12360, if it does will open the gate for 12420-12500 while on lower side 12280-12230 will act as immediate support.

Corporate News

Blackstone to invest Rs 380 cr in Allcargo's industrial and logistics parks

Private equity firm Blackstone will invest as much as Rs 380 crore in Allcargo Logistics to develop industrial and logistics parks across India. Blackstone's investment in the platform will be through debt and equity, Allcargo said in a statement. Allcargo will retain a minority stake in various logistics assets and transfer its debt as it relates to these specific assets to their relevant subsidiaries, it said. The transaction is expected to conclude in a phase wise manner over the next 12 months, subject to satisfaction of customary closing conditions and achievement of certain milestones. "The Indian warehousing sector is scaling an expansionary curve backed by a robust regulatory environment and government thrust in boosting manufacturing, e-commerce and organised retail. This sector has emerged as an attractive investment destination for global investors. Through this strategic tie-up, we reiterate our commitment and positioning to create a global benchmark in warehousing infrastructure and provide state-of-the-art warehousing solutions to our customers," Shashi Kiran Shetty, Chairman, Allcargo Logistics Ltd, said. (Source: Businessline)

Tata Elxsi Q3 net profit up over 14 per cent to Rs 75.4 crore

Tata Elxsi on Monday said its net profit has increased 14.2 per cent to Rs 75.42 crore for the December 2019 quarter. The company had registered a net profit of Rs 65.99 crore in the year-ago period, Tata Elxsi said in a regulatory filing. Its revenue from operations rose over 4 per cent to Rs 423.43 crore for the said quarter from Rs 407 crore for the corresponding period a year ago, it added. Software development and services contributed Rs 409.8 crore, while system integration and support services accounted for Rs 13.63 crore of the said quarter's revenue. In a statement, the company said it had reported all-round quarter-on-quarter (q-o-q) growth across key verticals, business divisions and geographies in the reported quarter. (Source: Businessline)

Alembic gets USFDA nod for Vilazodone Hydrochloride tablets used to treat depression

Drug firm Alembic Pharmaceuticals on Monday said it has received a final nod from US health regulator for Vilazodone Hydrochloride tablets used for treatment of depression. "The company has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Vilazodone Hydrochloride tablets, 10 mg, 20 mg, and 40 mg," Alembic said in a filing to BSE. Vilazodone Hydrochloride tablets are indicated for the treatment of major depressive disorder. "The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Viibryd tablets, 10 mg, 20 mg, and 40 mg, of Allergan Sales," the drug firm said. Citing IQVIA, the company said Hydrochloride tablets, 10 mg, 20 mg, and 40 mg, have an estimated market size of USD 469 million for 12 months ending September 2019. Alembic had previously received tentative approval for this ANDA. "Alembic was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification and hence is eligible for 180 days of shared exclusivity," it said. The launch of the product will be as per settlement agreement with US-based pharmaceutical firm Allergan. (Source: Businessline)

Morning Wealth

Nifty Top 5 Gainers	Close	Pts. Chg	% Chg
INFY	774	35.4	4.8
INDUSINDBK	1540	48.4	3.3
COALINDIA	212	6.3	3.0
GAIL	129	3.6	2.8
BHARTIARTL	469	11.9	2.6

Nifty Top 5 Losers	Close	Pts. Chg	% Chg
YESBANK	42	-2.7	-5.9
UPL	592	-8.3	-1.4
INFRATEL	246	-3.0	-1.2
TCS	2190	-23.2	-1.1
EICHERMOT	20280	-152.8	-0.8

Int. Indices	Close	Pts. Chg	% Chg
S&P 500	3288.1	22.8	0.7
Dow 30	28907.1	83.3	0.3
Nasdaq	9273.9	95.1	1.0
FTSE 100	7617.6	29.8	0.4
DAX	13451.5	-31.8	-0.2
CAC 40	6036.1	-1.0	0.0
Nikkei 225	24020.0	169.4	0.7
Hang Seng	28999.8	44.8	0.2
STI Index	3262.1	11.1	0.3

ADR	Close	Pts. Chg	% Chg
HDFC Bank	62.9	1.0	1.5
ICICI Bank	15.1	0.0	0.3
Infosys	10.9	0.2	2.1
Tata Motors	13.7	0.1	0.8
Wipro	3.9	0.1	1.3

Currencies	Close	Pts. Chg	% Chg
Dollar Index	97.3	-0.2	0.2
USD/INR	70.7	0.1	-0.2
EURO/INR	78.8	0.0	0.0
USD/YEN	110.1	-0.5	0.5

Commodities	Close	Pts. Chg	% Chg
Gold Rs	39546.0	-325.0	-0.8
Silver Rs	46443.0	-468.0	-1.0
Crude (Brent) \$	64.4	0.2	0.3
Crude Oil (WTI) \$	58.2	0.2	0.3

Economy

Clean power push: Govt adds over 50,000 MW in 5 years

The renewable energy sector has made rapid strides under the Modi government with 50 GW plus of new capacity coming into the grid in the last five years. This is despite the doubts being raised over the government's target of achieving of 175 GW by 2022. The December quarter of 2019 saw India's cumulative clean energy capacity cross 85,000 MW, of which more than 50,000 MW of new capacity addition was achieved in the past five years. As on December 31, 2019, the total grid-connected installed renewable power capacity in India stood at 85,908 MW, aided by support of several policy measures in recent years, according to Ministry of New and Renewable (MNRE) energy data. Five years ago, India's cumulative grid-interactive clean energy installed capacity was about 33,792 MW. Though the wind segment is still leading now with a total installed capacity of 37,505 MW as of December 31, 2019, solar is fast growing and is likely to overtake the wind sector in the next fiscal. The solar segment's (which includes ground-mounted and rooftop) total capacity was 33,730 MW as of December 2019. To achieve the 175 GW target by 2022, the sector has to set up 90 GW capacity. (Source: Businessline)

International News

Donald Trump's trade deal rouses conundrum of trusting China to deliver

After three years of tweets and tariffs, United States (US) President Donald Trump has arrived at his China moment. With the signing of the 'phase one' deal on Wednesday, Trump will deliver at least a partial agreement many skeptics doubted was ever possible. The deal includes Chinese commitments to respect American intellectual property, not manipulate its currency, and a US expectation for \$200 billion in new purchases that should help reduce a yawning trade deficit and repair some of the damage suffered by farmers. But even that political victory leaves Trump confronting the same China conundrum that has plagued his predecessors. The broad and bipartisan agreement in Washington is that American presidents have for decades been hoodwinked by a China that has often failed to deliver on its promises. Trump and his lieutenants, of course, insist that this time is different, that experts who see phase one as a re-branding of old guarantees are wrong. Unlike agreements negotiated by prior administrations, this one is enforceable, they say, and there will be real and immediate economic repercussions for China if it comes up short. (Source: Businessline)

Major Bulk Deal (NSE)

Scrip Name	Qty	Type	Client Name	Trade Price
TACL	53485	SELL	HDFC STANDARD LIFE INSURANCE CO LTD	535

Major Bulk Deal (BSE)

Scrip Name	Qty	Type	Client Name	Trade Price
NO MAJOR BULK DEALS				

(Source: Investing.com and BSE)



Research Desk

Tel: +91 22 61596406

Institutional Sales Desk

Tel: +91 22 61596403/04/05

Disclaimer Appendix**Analyst (s) holding in the Stock : Nil****Analyst (s) Certification:**

We analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer (s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation (s) or view (s) in this report. Analysts aren't registered as research analysts by FINRA and might not be an associated person of the BP Equities Pvt. Ltd. (Institutional Equities).

General Disclaimer

This report has been prepared by the research department of BP EQUITIES Pvt. Ltd, is for information purposes only. This report is not construed as an offer to sell or the solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal.

BP EQUITIES Pvt. Ltd have exercised due diligence in checking the correctness and authenticity of the information contained herein, so far as it relates to current and historical information, but do not guarantee its accuracy or completeness. The opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time. Prospective investors are cautioned that any forward looking statement are not predictions and are subject to change without prior notice.

Recipients of this material should rely on their own investigations and take their own professional advice. BP EQUITIES Pvt. Ltd or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. BP EQUITIES Pvt. Ltd. or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

BP EQUITIES Pvt. Ltd and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by any person in any locality, state and country or other jurisdiction where such distribution, publication or use would be contrary to the law or regulation or would subject to BP EQUITIES Pvt. Ltd or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Corporate Office:

4th floor,
Rustom Bldg,
29, Veer Nariman Road, Fort,
Mumbai-400001
Phone- +91 22 6159 6464
Fax-+91 22 6159 6160
Website- www.bpwealth.com

Registered Office:

24/26, 1st Floor, Cama Building,
Dalal street, Fort,
Mumbai-400001

BP Equities Pvt. Ltd.**CIN No: U67120MH1997PTC107392**